Sleep Control, GPCRs, and Glucose Metabolism.
Study Goal
The researchers aimed to explore the beneficial impact of sleep on glucose metabolism and suggest therapeutic interventions, including melatonin agonists, for sleep-related metabolic disorders.
Results Summary
The abstract highlights melatonin agonists as a treatment for sleep disorders but does not provide specific results on their effects on glucose metabolism. It emphasizes the need for deeper understanding of these medications' mechanisms in diabetic patients.
Population
Diabetic patients with sleep disorders (implied, not explicitly stated).
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
Modern lifestyles prolong daily activities into the nighttime | decrease | circadian rhythms | - | - | disrupting | #1 |
disrupted circadian rhythms | increase | sleep disturbances | - | - | may cause | #2 |
Sleep disturbances | increase | blood glucose levels | - | - | have been implicated in the dysregulation of | #3 |
Sleep disturbances | increase | type 2 diabetes (T2D) | - | - | reported to increase the risk of | #4 |
Sleep disturbances | increase | diabetic complications | - | - | reported to increase the risk of | #5 |
anti-insomnia drugs that target ionotropic and G protein-coupled receptors (GPCRs) | decrease | sleep disorders | - | - | are used to treat | #6 |
γ-aminobutyric acid (GABA) agonists | decrease | sleep disorders | - | - | are used to treat | #7 |
melatonin agonists | decrease | sleep disorders | - | - | are used to treat | #8 |
orexin receptor antagonists | decrease | sleep disorders | - | - | are used to treat | #9 |
sleep | increase | glucose metabolism | - | - | has a beneficial impact on | #10 |
Modern lifestyles prolong daily activities into the nighttime, disrupting circadian rhythms, which may cause sleep disturbances. Sleep disturbances have been implicated in the dysregulation of blood glucose levels and reported to increase the risk of type 2 diabetes (T2D) and diabetic complications. Sleep disorders are treated using anti-insomnia drugs that target ionotropic and G protein-coupled receptors (GPCRs), including γ-aminobutyric acid (GABA) agonists, melatonin agonists, and orexin receptor antagonists. A deeper understanding of the effects of these medications on glucose metabolism and their underlying mechanisms of action is crucial for the treatment of diabetic patients with sleep disorders. In this review we focus on the beneficial impact of sleep on glucose metabolism and suggest a possible strategy for therapeutic intervention against sleep-related metabolic disorders.